Indacaterol

beta2-Adrenergic Agonist — RESPIRATORY SYSTEM

Key facts

Indacaterol is an ofm drug in the beta2-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the EMA in 2009. Its mechanism of action is classified as Adrenergic beta2-Agonists. DrugCentral lists 16 molecular targets, including Adrb2, ADRB2 and SLC6A3. Recorded indications include Asthma, Bronchospasm Prevention with COPD, Prevention of Bronchospasm with Chronic Bronchitis and Prevention of Bronchospasms with Emphysema.

• Approval status: ofm (first approved 2009 by the EMA).
• Drug class: beta2-Adrenergic Agonist.
• Mechanism of action: Adrenergic beta2-Agonists.
• Molecular targets: Adrb2, ADRB2, SLC6A3 and ADRB1 (16 listed in DrugCentral).
• Indications: Asthma, Bronchospasm Prevention with COPD, Prevention of Bronchospasm with Chronic Bronchitis and Prevention of Bronchospasms with Emphysema.
• ATC code: R03AC18 (Selective beta-2-adrenoreceptor agonists).
• Molecular formula: C24H28N2O3; molecular weight 392.50 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Asthma
• Bronchospasm Prevention with COPD
• Prevention of Bronchospasm with Chronic Bronchitis
• Prevention of Bronchospasms with Emphysema

Contraindications (12)

• Acutely Deteriorating Chronic Obstructive Pulmonary Disease
• Chronic myocardial ischemia
• Conduction disorder of the heart
• Congenital long QT syndrome
• Diabetes mellitus
• Exacerbation of asthma
• Hyperglycemia
• Hypertensive disorder
• Hypokalemia
• Prolonged QT interval
• Seizure disorder
• Thyrotoxicosis

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta2-Agonists
• Established pharmacologic class: beta2-Adrenergic Agonist

Molecular targets (16)

Target	Gene	Action	Activity
Beta-2 adrenergic receptor	Adrb2	unknown	IC50 8.10
Beta-2 adrenergic receptor	ADRB2	agonist	Ki 7.80
Sodium-dependent dopamine transporter	SLC6A3	unknown	Ki 7.12
Beta-1 adrenergic receptor	ADRB1	unknown	Ki 7.04
Transmembrane protein 97	TMEM97	unknown	Ki 6.97
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 6.45
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 6.25
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 6.14
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 6.11
D(3) dopamine receptor	DRD3	unknown	Ki 5.98
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 5.75
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 5.70
Alpha-1B adrenergic receptor	ADRA1B	unknown	Ki 5.36
Serine/arginine-rich splicing factor 6	SRSF6	unknown	IC50 4.72
D(2) dopamine receptor	DRD2	unknown	IC50 4.60
Cytochrome P450 1B1	CYP1B1	unknown	IC50 4.23

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2020-06-29	PMDA	—	Novartis Pharma K.K.
2011-07-01	FDA	—	NOVARTIS
2009-11-29	EMA	—	Novartis Europharm Limited

ATC classification

ATC code	Therapeutic hierarchy
R03AC18	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Selective beta-2-adrenoreceptor agonists
R03AK14	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
R03AL04	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
R03AL12	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: UGT1A1 · Informative PGx
• FDA label: UGT1A1 · No Clinical PGx
• HCSC label: UGT1A1 · No Clinical PGx
• PMDA label: UGT1A1 · Actionable PGx
• Swissmedic label: UGT1A1 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Bacterial disease carrier	299.8
Bronchial secretion retention	253.7
Superinfection	249.1
Bronchospasm	209.6
Dyspnoea	186.2
Scoliosis	185.1
Hyper IgE syndrome	169.6
Sleep disorder due to a general medical condition	141.8
Sinus operation	136.1
Asthma	135.4
Eosinophilia	134.0
Rib fracture	133.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Indacaterol is on its molecule page.

• Molecular formula: C₂₄H₂₈N₂O₃
• Molecular weight: 392.50 g/mol
• CAS number: 312753-06-3
• InChIKey: QZZUEBNBZAPZLX-QFIPXVFZSA-N
• PubChem CID: 6918554

CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Indacaterol used for?

DrugCentral lists the following indications for Indacaterol: Asthma, Bronchospasm Prevention with COPD, Prevention of Bronchospasm with Chronic Bronchitis and Prevention of Bronchospasms with Emphysema.

How does Indacaterol work?

Indacaterol is classified as Adrenergic beta2-Agonists; its molecular targets in DrugCentral include Adrb2, ADRB2 (agonist), SLC6A3 and ADRB1.

When was Indacaterol first approved?

Indacaterol was first approved by the EMA in 2009.

What drug class does Indacaterol belong to?

Indacaterol is in the beta2-Adrenergic Agonist class.

What is the chemical formula of Indacaterol?

Indacaterol has the molecular formula C24H28N2O3 and a molecular weight of 392.50 g/mol.

Sources

• DrugCentral drug card 4183 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1095777 — compound record and bioactivity
• PubChem CID 6918554 — chemical identifiers
• DrugBank DB05039 — drug record
• FDA UNII 8OR09251MQ — substance identity
• DailyMed: FDA labels for Indacaterol — current prescribing information (label search)
• UniProt P07550 (ADRB2) — target protein
• UniProt Q01959 (SLC6A3) — target protein
• UniProt P08588 (ADRB1) — target protein
• UniProt Q5BJF2 (TMEM97) — target protein
• UniProt P35348 (ADRA1A) — target protein
• UniProt P23975 (SLC6A2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.